John M Kittelson
Overview
Explore the profile of John M Kittelson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
646
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goldenberg N, Schulman S, Kittelson J, Abshire T, Casella J, Dale R, et al.
J Thromb Haemost
. 2024 Oct;
23(2):651-656.
PMID: 39461724
Background: The Multicenter Evaluation of the Duration of Therapy for Thrombosis in Children multinational, randomized clinical trial revealed noninferiority of a 6-week vs 3-month duration of anticoagulation for the treatment...
2.
Goldenberg N, Kittelson J, Abshire T, Bonaca M, Casella J, Dale R, et al.
JAMA
. 2022 Jan;
327(2):129-137.
PMID: 35015038
Importance: Among patients younger than 21 years of age, the optimal duration of anticoagulant therapy for venous thromboembolism is unknown. Objective: To test the hypothesis that a 6-week duration of...
3.
Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Sharifova G, et al.
Thromb Haemost
. 2021 Apr;
121(12):1684-1695.
PMID: 33823560
Coronavirus disease-2019 (COVID-19) has been associated with significant risk of venous thromboembolism (VTE), arterial thromboembolism (ATE), and mortality particularly among hospitalized patients with critical illness and elevated D-dimer (Dd) levels....
4.
Hu J, Blatchford P, Goldenberg N, Kittelson J
Stat Med
. 2020 Oct;
39(26):3823-3839.
PMID: 33048360
Although all clinical trials are designed and monitored using more than one endpoint, methods are needed to assure that decision criteria are chosen to reflect the clinically relevant tradeoffs that...
5.
Bonaca M, Bauersachs R, Anand S, Sebastian Debus E, Nehler M, Patel M, et al.
N Engl J Med
. 2020 Mar;
382(21):1994-2004.
PMID: 32222135
Background: Patients with peripheral artery disease who have undergone lower-extremity revascularization are at high risk for major adverse limb and cardiovascular events. The efficacy and safety of rivaroxaban in this...
6.
Capell W, Bonaca M, Nehler M, Chen E, Kittelson J, Anand S, et al.
Am Heart J
. 2018 May;
199:83-91.
PMID: 29754671
Background: Patients with peripheral artery disease (PAD) undergoing a lower-extremity revascularization are at heightened risk for ischemic cardiac and limb events. Although intensification of antithrombotic therapy after revascularization has demonstrated...
7.
Kittelson J, Steg P, Halperin J, Goldenberg N, Schulman S, Spyropoulos A, et al.
Thromb Haemost
. 2016 Jun;
116(3):544-53.
PMID: 27346176
Clinical trials of antithrombotic therapy require a cohesive assessment of benefit and risk. A new graphical method to represent the bivariate relation of benefit and risk in trials of antithrombotic...
8.
Goldenberg N, Takemoto C, Yee D, Kittelson J, Patricia Massicotte M
Blood
. 2015 Oct;
126(24):2541-7.
PMID: 26500341
Venous thromboembolism (VTE) is increasingly diagnosed in pediatric patients, and anticoagulant use in this population has become common, despite the absence of US Food and Drug Administration (FDA) approval for...
9.
Shea K, Gavin K, Melanson E, Gibbons E, Stavros A, Wolfe P, et al.
Menopause
. 2015 Mar;
22(10):1045-52.
PMID: 25783468
Objective: Suppression of ovarian hormones in premenopausal women on gonadotropin-releasing hormone agonist (GnRH(AG)) therapy can cause fat mass (FM) gain and fat-free mass (FFM) loss. Whether this is specifically caused...
10.
Bade M, Kittelson J, Kohrt W, Stevens-Lapsley J
Am J Phys Med Rehabil
. 2014 Feb;
93(7):579-85.
PMID: 24508937
Objective: The aim of this study was to assess the predictive value of functional performance and range of motion measures on outcomes after total knee arthroplasty. Design: This is a...